FGFR2 and gastric cancer: These include the multi-kinase inhibitor derazantinib, which is currently being tested as monotherapy as well as in combination with anti-PD-1 or chemotherapy in FGFR2-altered GC (NCT04604132), and anlotinib, which is currently being tested in combination with chemotherapy in patients with metastatic GC (ChiCTR1900026291).